Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omicron BA.4/5-Delta Vaccine Immunogenicity and Safety in Adults
NCT05850507Completed
- Sponsor
- Zhifei Biological
- Start
- Mar 2023
- Primary completion
- Oct 2023
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Randomised, double-blind trial of Omicron BA.4/5-Delta recombinant protein vaccine in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Zhifei Biological. Primary endpoints: Incidence of all adverse events at 30 days, Incidence of serious adverse events at 6 months and 2 more. Started Mar 2023; status: completed.
02
Drugs
Omicron BA.4/5-Delta recombinant protein vaccine
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05850507.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05850507.